News

Become a speaker at PharmaLab 2025 - Analytics, Bioanalytics, Microbiology and more

The 13th PharmaLab Congress from November 24-28, 2025 will take place as usual in Neuss/Düsseldorf with two pre-conference workshops and several parallel conferences. As always, it offers you the opportunity to become part of the speaker team and submit a presentation to share your knowledge with colleagues and discuss the respective experiences. So, become part of the team of speakers - and submit your proposal for a presentation via our online form.

More
14 Submissions for the Professor Wallhäußer Award for Innovations in GMP and Pharmaceutical Technology 2025

The Professor Wallhäußer Award for Innovations in GMP and Pharmaceutical Technology will once again be presented at the PharmaCongress on 8 and 9 April in Wiesbaden. This year, 14 projects have applied for the award, with topics ranging from optimised technology to AI applications.

More
USP publishes Draft Chapter on Contamination Control Strategy

With the draft chapter <1110>, the USP completes its programme with recommendations on the subject of contamination control strategy, as already called for in other documents.

More
From Burkholderia to Ethylene Glycol - a List of Deficiencies at a Manufacturer of OTC Products

A manufacturer of OTC products from Mesquite, Texas received a Warning Letter from the US FDA for deficiencies in various areas ranging from microbiology and raw material analysis to cleaning and disinfection.

More
Inadequate Microbiological Testing of Nonsterile Products - FDA Warning Letter

In a Warning Letter to a manufacturer of non-sterile drugs, the FDA criticized, among other deficiencies, a lack of testing of the manufactured batches for microbiological quality in accordance with USP chapters <61> and <62>, which deal with the "Enumeration" test and the test for "Specified Microorganisms".

More
EMA Q&A - When is Testing for Endotoxin Masking Effects necessary for biological Products?

The EMA has recently published an update to its question and answer catalog for biological medicinal products. Among other things, it also addresses the question of when endotoxin masking effects must be taken into account for biological products.

More
Revision of USP chapter <1071> on rapid methods and its effect on other USP chapters

United States Pharmacopoeia publishes an overview of the effects of the revision of Chapter <1071>  “Rapid Microbial Tests for Release of Sterile Short-Life Products: A Risk-Based Approach” on other USP chapters and guidance documents.

More
Warning Letter - No Testing for EC/DEG and other Deficiencies

In November, the FDA issued a warning letter to a manufacturer of topical products in France. In addition to inadequate testing of components used, e.g. for ethylene or diethylene glycol, the warning letter also includes a whole series of other deviations.

More
Anvisa - Alternativer Pyrogentest MAT im brasilianischen Arzneibuch

Auch die Anvisa hat sich dem internationalen Trend angeschlossen und mit der neuen 7. Version der brasilianischen Pharmakopoea den MAT als alternativen Pyrogentest aufgenommen.

More
Revision of USP <1085> "Guidelines on Endotoxin Test"

The USP continues to work on updating its chapters around endotoxin testing and is publishing a proposed revision to Chapter <1085> Guidelines on Endotoxin Test.

More
x
Search